A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

October 16, 2024

Study Completion Date

April 9, 2025

Conditions
Sarcoidosis, Pulmonary
Interventions
DRUG

Namilumab

Namilumab administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously to match namilumab dosing

Trial Locations (47)

1200

Kinevant Study Site, Brussels

3000

Kinevant Study Site, Leuven

5530

Kinevant Study Site, Yvoir

14165

Kinevant Study Site, Berlin

15213

Kinevant Study Site, Pittsburgh

19140

Kinevant Study Site, Philadelphia

21234

Kinevant Study Site, Baltimore

22042

Kinevant Study Site, Falls Church

22908

Kinevant Study Site, Charlottesville

27834

Kinevant Study Site, Greenville

29425

Kinevant Study Site, Charleston

29732

Kinevant Study Site, Rock Hill

29841

Kinevant Study Site, Augusta

30625

Kinevant Study Site, Hanover

32610

Kinevant Study Site, Gainesville

33110

Kinevant Study Site, Mersin

34134

Kinevant Study Site, Istanbul

35100

Kinevant Study Site, Izmir

35233

Kinevant Study Site, Birmingham

35330

Kinevant Study Site, Izmir

44195

Kinevant Study Site, Cleveland

45219

Kinevant Study Site, Cincinnati

45239

Kinevant Study Site, Essen

52242

Kinevant Study Site, Iowa City

55414

Kinevant Study Site, Minneapolis

55905

Kinevant Study Site, Rochester

59037

Kinevant Study Site, Lille

60612

Kinevant Study Site, Chicago

66160

Kinevant Study Site, Kansas City

69126

Kinevant Study Site, Heidelberg

70115

Kinevant Study Site, New Orleans

75018

Kinevant Study Site, Paris

75390

Kinevant Study Site, Dallas

77030

Kinevant Study Site, Houston

79106

Kinevant Study Site, Freiburg im Breisgau

80206

Kinevant Study Site, Denver

91355

Kinevant Study Site, Valencia

93000

Kinevant Study Site, Bobigny

94304

Kinevant Study Site, Palo Alto

B-4000

Kinevant Study Site, Liège

2333 ZA

Kinevant Study Site, Leiden

3435 CM

Kinevant Study Site, Nieuwegein

3015 GD

Kinevant Study Site, Rotterdam

06620

Kinevant Study Site, Ankara

CB20QQ

Kinevant Study Site, Cambridge

HU165JQ

Kinevant Study Site, Cottingham

SE59RS

Kinevant Study Site, London

Sponsors
All Listed Sponsors
lead

Kinevant Sciences GmbH

INDUSTRY